检索结果-南通市图书馆

Bone marrow mesenchymal stem cell transplantation combined with perindopril treatment attenuates infarction remodelling in a rat model of acute myocardial infarction

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Journal of zhejiang university-Science B(Biomedicine & Biotechnology) 2006年第8期7卷 641-647页

作者： wang jian-an LUO Rong-hua zhang xing xie xiao-jie HU Xin-yang HE Ai-na CHEN jie LI Jia-hui Department of cardiology the Second Affiliated Hospital School of Medicine Zhejiang University Hangzhou 310009 China Center of Lab Sir Run Run Shaw Hospital School of Medicine Zhejiang University Hangzhou 310016 China

Objective: This study was performed to evaluate whether implantation of mesenchymal stem cell (MSC) would reduce left ventricular remodelling from the molecular mechanisms compared with angiotensin-converting enzyme inhibitors (ACEIs) perindopril into ischemic myocardium after acute myocardial infarction. Methods: Forty rats were divided into four groups: control, MSC, ACEI, MSC+ACEI groups. Bone marrow stem cell derived rat was injected immediately into a zone made ischemic by coronary artery ligation in MSC group and MSC+ACEI group. Phosphate-buffered saline (PBS) was injected into control group. Perindopril was administered p.o. to ACEI group and MSC+ACEI group. Six weeks after implantation, the rats were killed and heart sample was collected. Fibrillar collagen was observed by meliorative Masson’s trichome stain. Western Blotting was employed to evaluate the protein expression of matrix metalloproteinase (MMP)-2, matrix metalloproteinase (MMP)-9 in infarction zone. The transcriptional level of MMP2, MMP9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 in infarction area was detected by reverse transcriptase PCR (RT-PCR) analysis. Results: The fibrillar collagen area, the protein expression of MMP2, MMP9 and the transcriptional level of MMP2, MMP9 mRNA in infarction zone reduced in MSC group, ACEI group, and MSC+ACEI group. No significant difference was detected in the expression of TIMP1 mRNA among the 4 groups. Conclusion: Both MSC and ACEI could reduce infarction remodelling by altering collagen metabolism.

关键词： Remodelling Acute myocardial infarction Perindopril Bone marrow mesenchymal stem cell

Medical expenditure for esophageal cancer in china:a 10-year multicenter retrospective survey(2002-2011)

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2017年第11期36卷 548-559页

作者： Lan-Wei Guo Hui-Yao Huang Ju-Fang Shi Li-Hong Lv Ya-Na Bai A-Yan Mao Xian-Zhen Liao Guo-Xiang Liu jian-Song Ren xiao-jie Sun Xin-Yu Zhu Jin-Yi Zhou Ji-Yong Gong Qi Zhou Lin Zhu Yu-Qin Liu Bing-Bing Song Ling-Bin Du xiao-Jing xing Pei-An Lou xiao-Hua Sun xiao Qi Shou-Ling Wu Rong cao Li Lan Ying Ren Kai zhang jie He jian.Gong zhang Min Dai Department of Cancer Epidemiology Henan Office for Cancer Control and Research The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital No. 127 Dongming Road Zhengzhou 450008 Henan P. R China Program Office for Cancer Screening in Urban china Cancer Hospital Chinese Academy of Medical Sciences (CAMS) Peking Union Medical College National Cancer Center of China No. 17 Panjiayuannanli Chaoyang District Beijing 100021 P. R. China Department of Human Resources The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou 450008 Henan P. R. China Institute of Epidemiology and Health Statistics Lanzhou University Lanzhou 730000 Gansu P. R. China Public Health Information Research Office Institute of Medical Information Chinese Academy of Medical Sciences (CAMS) Beijing 100020 P. R. China Hunan Office for Cancer Control and Research Hunan Provincial Cancer Hospital Changsha 410006 Hunan P. R. China Department of Health Economics School of Health Management Harbin Medical University Harbin 150081 Heilongjiang P. R. China Center for Health Management and Policy Key Lab of Health Economics and Policy Shandong University Jinan 250012 Shandong P. R. China Institute of Chronic Non.Communicable Diseases Prevention and Control Jiangsu Provincial Center for Disease Control and Prevention Nanjing 210009 Jiangsu P. R. China Science and Education Department Public Health division Shandong Tumor Hospital Jinan 250117 Shandong P. R. China Chongqing Office for Cancer Control and Research Chongqing Cancer hospital Chongqing 400030 P. R. China Teaching and Research Department Affiliated Cancer Hospital of Xinjiang Medical University ürümqi 830011 Xinjiang P. R. China Cancer Epidemiology Research Center Gansu Provincial Cancer Hospital Lanzhou 730050 Gansu P. R. China Heilongjiang Office for Cancer Control and Research Affiliated Cancer Hospital of Harbin Medical University Harbin 150081 Heilongjiang P R. China zhejiang Office for Cancer

Background: Esophageal cancer is associated with substantial disease burden in china, and data on the economic burden are fundamental for setting priorities in cancer interventions. The medical expenditure for the diagnosis and treatment of esophageal cancer in china has not been fully quantified. This study aimed to examine the medical expenditure of Chinese patients with esophageal cancer and the associated ***: From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 37 hospitals in 13 provinces/municipalities across china as a part of the Cancer Screening Program of Urban china. For each esophageal cancer patient diagnosed between 2002 and 2011, clinical information and expense data were extracted by using structured questionnaires. All expense data were reported in Chinese Yuan(CNY; 1 CNY = 0.155 USD) based on the2011 value and inflated using the year-specific health care consumer price index for ***: A total of 14,967 esophageal cancer patients were included in the analysis. It was estimated that the overall average expenditure per patient was 38,666 CNY, and an average annual increase of 6.27% was observed from 2002(25,111 CNY) to 2011(46,124 CNY). The average expenditures were 34,460 CNY for stage Ⅰ,39,302 CNY for stage Ⅱ,40,353 CNY for stage Ⅲ, and 37,432 CNY for stage IV diseases(P nditure also differed by the therapy type, which was 38,492 CNY for surgery, 27,933 CNY for radiotherapy, and 27,805 CNY for chemotherapy(P 2% of the overall ***: These conservative estimates suggested that medical expenditures for esophageal cancer in china substantially increased in the last 10 years, treatment for early-stage esophageal cancer costs less than that for advanced cases, and spending on drugs continued to account for a considerable proportion of the overall expenditure.

关键词： Esophageal neoplasms Medical expenditure Diagnosis and treatment china

Evidence for particle acceleration approaching PeV energies in the W51 complex

在线全文

学校读者我要写书评

暂无评论

Science Bulletin 2024年第18期69卷 2833-2841页

作者： LHAASO Collaboration Zhen cao F.Aharonian Axikegu Y.X.Bai Y.W.Bao D.Bastieri X.J.Bi Y.J.Bi W.Bian A.V.Bukevich Q.cao W.Y.cao Zhe cao J.Chang J.F.Chang A.M.Chen E.S.Chen H.X.Chen Liang Chen Lin Chen Long Chen M.J.Chen M.L.Chen Q.H.Chen S.Chen S.H.Chen S.Z.Chen T.L.Chen Y.Chen N.Cheng Y.D.Cheng M.Y.Cui S.W.Cui X.H.Cui Y.D.Cui B.Z.Dai H.L.Dai Z.G.Dai Danzengluobu X.Q.Dong K.K.Duan J.H.Fan Y.Z.Fan J.Fang J.H.Fang K.Fang C.F.Feng H.Feng L.Feng S.H.Feng X.T.Feng Y.Feng Y.L.Feng S.Gabici B.Gao C.D.Gao Q.Gao W.Gao W.K.Gao M.M.Ge L.S.Geng G.Giacinti G.H.Gong Q.B.Gou M.H.Gu F.L.Guo X.L.Guo Y.Q.Guo Y.Y.Guo Y.A.Han M.Hasan H.H.He H.N.He J.Y.He Y.He Y.K.Hor B.W.Hou C.Hou X.Hou H.B.Hu Q.Hu S.C.Hu D.H.Huang T.Q.Huang W.J.Huang X.T.Huang X.Y.Huang Y.Huang X.L.Ji H.Y.Jia K.Jia K.jiang X.W.jiang Z.J.jiang M.Jin M.M.Kang I.Karpikov D.Kuleshov K.Kurinov B.B.Li C.M.Li Cheng Li Cong Li D.Li F.Li H.B.Li H.C.Li jian Li jie Li K.Li S.D.Li W.L.Li W.L.Li X.R.Li Xin Li Y.Z.Li Zhe Li Zhuo Li E.W.Liang Y.F.Liang S.J.Lin B.Liu C.Liu D.Liu D.B.Liu H.Liu H.D.Liu J.Liu J.L.Liu M.Y.Liu R.Y.Liu S.M.Liu W.Liu Y.Liu Y.N.Liu Q.Luo Y.Luo H.K.Lv B.Q.Ma L.L.Ma X.H.Ma J.R.Mao Z.Min W.Mitthumsiri H.J.Mu Y.C.Nan A.Neronov L.J.Ou P.Pattarakijwanich Z.Y.Pei J.C.Qi M.Y.Qi B.Q.Qiao J.J.Qin A.Raza D.Ruffolo A.Sáiz M.Saeed D.Semikoz L.Shao O.Shchegolev X.D.Sheng F.W.Shu H.C.Song Yu.V.Stenkin V.Stepanov Y.Su D.X.Sun Q.N.Sun X.N.Sun Z.B.Sun J.Takata P.H.T.Tam Q.W.Tang R.Tang Z.B.Tang W.W.Tian C.wang C.B.wang G.W.wang H.G.wang H.H.wang J.C.wang Kai wang Kai wang L.P.wang L.Y.wang P.H.wang R.wang W.wang X.G.wang X.Y.wang Y.wang Y.D.wang Y.J.wang Z.H.wang Z.X.wang Zhen wang Zheng wang D.M.Wei J.J.Wei Y.J.Wei T.Wen C.Y.Wu H.R.Wu Q.W.Wu S.Wu X.F.Wu Y.S.Wu S.Q.Xi J.Xia G.M.Xiang D.X.xiao G.xiao Y.L.Xin Y.xing D.R.Xiong Z.Xiong D.L.Xu R.F.Xu R.X.Xu W.L.Xu L.Xue D.H.Yan J.Z.Yan T.Yan C.W.Yang C.Y.Yang F.Yang F.F.Yang L.L.Yang M.J.Yang R.Z.Yang W.X.Yang Y.H.Yao Z.G.Yao L.Q.Yin N.Yin X.H.You Z.Y.You Y.H.Yu Q.Yuan H.Yue H.D.Zeng T.X.Zeng W.Zeng M.Zha B.B.zhang F.zhang H.zhang 不详 Key Laboratory of Particle Astrophysics&Experimental Physics division&Computing Center Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China university of Chinese Academy of Sciences Beijing 100049China TIANFU Cosmic Ray Research Center ChengduChina Dublin Institute for Advanced Studies 31 Fitzwilliam Place2 DublinIreland Max-Planck-Institut for Nuclear Physics P.O.Box 103980Heidelberg 69029Germany School of Physical Science and Technology&School of Information Science and Technology Southwest Jiaotong UniversityChengdu 610031China School of Astronomy and Space Science Nanjing UniversityNanjing 210023China Center for Astrophysics Guangzhou UniversityGuangzhou 510006China Tsung-Dao Lee Institute&School of Physics and Astronomy Shanghai Jiao Tong UniversityShanghai 200240China Institute for Nuclear Research of Russian Academy of Sciences Moscow 117312Russia Hebei Normal university Shijiazhuang 050024China university of Science and Technology of china Hefei 230026China State Key Laboratory of Particle Detection and Electronics China Key Laboratory of Dark Matter and Space Astronomy&Key Laboratory of Radio Astronomy Purple Mountain ObservatoryChinese Academy of SciencesNanjing 210023China Research Center for Astronomical Computing Zhejiang LaboratoryHangzhou 311121China Key Laboratory for Research in Galaxies and Cosmology Shanghai Astronomical ObservatoryChinese Academy of SciencesShanghai 200030China School of Physics and Astronomy Yunnan UniversityKunming 650091China Key Laboratory of Cosmic Rays(Tibet university) Ministry of EducationLhasa 850000China National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China School of Physics and Astronomy(Zhuhai)&School of Physics(Guangzhou)&Sino-French Institute of Nuclear Engineering and Technology(Zhuhai) Sun Yat-sen UniversityZhuhai 519000&Guangzhou 510275GuangdongChina Institute of Frontier and Interdisciplinary Science Shandong UniversityQingdao 266237China APC UniversitéParis Cité

Theγ-ray emission from the W51 complex is widely acknowledged to be attributed to the interaction between the cosmic rays(CRs)accelerated by the shock of supernova remnant(SNR)W51C and the dense molecular clouds in the adjacent star-forming region,***,the maximum acceleration capability of W51C for CRs remains *** on observations conducted with the Large High Altitude Air Shower Observatory(LHAASO),we report a significant detection ofγrays emanating from the W51 complex,with energies from 2 to 200 *** LHAASO measurements,for the first time,extend theγ-ray emission from the W51 complex beyond 100 TeV and reveal a significant spectrum bending at tens of *** combining the"π^(0)-decay bump"featured data from Fermi-LAT,the broadbandγ-ray spectrum of the W51 region can be well-characterized by a simple pp-collision *** observed spectral bending feature suggests an exponential cutoff at~400 TeV or a power-law break at~200 TeV in the CR proton spectrum,most likely providing the first evidence of SNRs serving as CR accelerators approaching the PeV ***,two young star clusters within W51B could also be theoretically viable to produce the most energeticγrays observed by *** findings strongly support the presence of extreme CR accelerators within the W51 complex and provide new insights into the origin of Galactic CRs.

关键词： UHE c-ray Cosmic rays SNR W51C Star clusters

在线全文

学校读者我要写书评

暂无评论

Biomarkers of aging

Science china(Life Sciences) 2023年第5期66卷 893-1066页

作者： Aging Biomarker Consortium Hainan Bao jiani cao Mengting Chen Min Chen Wei Chen xiao Chen Yanhao Chen Yu Chen Yutian Chen Zhiyang Chen Jagadish K Chhetri Yingjie Ding Junlin Feng Jun Guo Mengmeng Guo Chuting He Yujuan Jia Haiping jiang Ying Jing Dingfeng Li Jiaming Li Jingyi Li Qinhao Liang Rui Liang Feng Liu xiaoqian Liu Zuojun Liu Oscar Junhong Luo jianwei Lv Jingyi Ma Kehang Mao Jiawei Nie Xinhua Qiao Xinpei Sun xiaoqiang Tang jianfang wang Qiaoran wang Siyuan wang Xuan wang Yaning wang Yuhan wang Rimo Wu Kai Xia Fu-Hui xiao Lingyan Xu Yingying Xu Haoteng Yan Liang Yang Ruici Yang Yuanxin Yang Yilin Ying Le zhang Weiwei zhang Wenwan zhang xing zhang Zhuo zhang Min Zhou Rui Zhou Qingchen Zhu Zhengmao Zhu Feng cao Zhongwei cao Piu Chan Chang Chen Guobing Chen Hou-Zao Chen Jun Chen Weimin Ci Bi-Sen Ding Qiurong Ding Feng Gao Jing-Dong JHan Kai Huang Zhenyu Ju Qing-Peng Kong Ji Li jian Li Xin Li Baohua Liu Feng Liu Lin Liu Qiang Liu Qiang Liu xingguo Liu Yong Liu Xianghang Luo Shuai Ma Xinran Ma Zhiyong Mao Jing Nie Yaojin Peng Jing Qu jie Ren Ruibao Ren Moshi Song Zhou Songyang Yi Eve Sun Yu Sun Mei Tian Shusen wang Si wang Xia wang xiaoning wang Yan-jiang wang Yunfang wang Catherine CL Wong Andy Peng Xiang Yichuan xiao Zhengwei xie Daichao Xu Jing Ye Rui Yue Cuntai zhang Hongbo zhang Liang zhang Weiqi zhang Yong zhang Yun-Wu zhang Zhuohua zhang Tongbiao Zhao Yuzheng Zhao Dahai Zhu Weiguo Zou Gang Pei Guang-Hui Liu Aging Biomarker Consortium(ABC) Beijing 100101China CAS Key Laboratory of Genomic and Precision medicine Beijing Institute of GenomicsChinese Academy of Sciences and China National Center for BioinformationBeijing 100101China State Key Laboratory of Stem Cell and Reproductive Biology Institute of ZoologyChinese Academy of SciencesBeijing 100101China Department of Dermatology Xiangya HospitalCentral South UniversityChangsha 410008China Hunan Key Laboratory of Aging Biology Xiangya HospitalCentral South UniversityChangsha 410008China National Clinical Research Center for Geriatric Disorders Xiangya HospitalCentral South UniversityChangsha 410008China Clinic Center of Human Gene Research Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Hubei Clinical Research Center of Metabolic and Cardiovascular Disease Huazhong University of Science and TechnologyWuhan 430022China Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging Huazhong University of Science and TechnologyWuhan 430022China Stem Cell Translational Research Center Tongji HospitalTongji University School of MedicineShanghai 200065China Department of Nuclear medicine Daping HospitalThird Military Medical UniversityChongqing 400042China CAS Key Laboratory of Nutrition Metabolism and Food SafetyShanghai Institute of Nutrition and HealthUniversity of Chinese Academy of SciencesChinese Academy of SciencesShanghai 200031China Shanghai Key Laboratory of Maternal Fetal medicine Clinical and Translational Research Center of Shanghai First Maternity and Infant HospitalFrontier Science Center for Stem Cell ResearchShanghai Key Laboratory of Signaling and Disease ResearchSchool of Life Sciences and TechnologyTongji UniversityShanghai 200092China The Department of Endovascular Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Key Laboratory of Regenerative medicine of Ministry of Education Institute of Ageing and Regenerative MedicineJ

Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological *** a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly *** immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this ***,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory *** fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant.

关键词： aging senescence biomarker clock

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： Jun Liu Dan-Dan Li Wei Dong Yu-Qi Liu Yang Wu Da-Xuan Tang Fu-Chun zhang Meng Qiu Qi Hua Jing-Yu He Jun Li Bai Du Ting-Hai Du Lin-Lin Niu Xue-Jun jiang Bo Cui jiang-Bin Chen Yang-Gan wang Hai-Rong wang Qin Yu Jing He Yi-Lin Mao xiao-Fang Bin Yue Deng Yu-Dan Tian Qing-Hua Han Da-Jin Liu Li-Qin Duan Ming-Jun Zhao Cui-Ying zhang Hai-Ying Dai Ze-Hua Li Ying xiao You-Zhi Hu xiao-Yu Huang Kun xing Xin jiang Chao-Feng Liu Jing An Feng-Chun Li Tao Tao Jin-Fa jiang Ying Yang Yao-Rong Dong Lei zhang Guang Fu Ying Li Shu-Wei Huang Li-Ping Dou Lan-Jun Sun Ying-Qiang Zhao jie Li Yun Xia Jun Liu Fan Liu Wen-Jin He Ying Li jian-Cong Tan Yang Lin Ya-Bin Zhou jian-Fei Yang Guo-Qing Ma Hui-Jun Chen He-Ping Liu Zong-Wu Liu jian-Xiong Liu xiao-Jia Luo xiao-Hong Bin Ya-Nan Yu Hai-Xia Dang Bing Li Fei Teng wang-Min Qiao xiao-Long Zhu Bing-Wei Chen Qi-Guang Chen Chun-Ti Shen Yong-Yan wang Yun-Dai Chen Zhong wang Institute of Basic Research in Clinical medicine China Academy of Chinese Medical SciencesBeijingChina Department of cardiology Chinese PLA General HospitalBeijingChina Department of cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina affiliated Zhongshan hospital of Dalian university DalianLiaoningChina Department of cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of cardiology Changsha Central HospitalChangshaHunanChina Department of cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of cardiology Shanghai Tongji HospitalShanghaiChina Department of cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of cardiology The First Hospital of ChangshaChangshaHunanChina Department of cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch